“LICONINE^®”, an Extract of Glycyrrhiza Uralensis, Normalizes the Fecal Microbiota Disturbance in Diet-induced Obese Mice

Yuka Sasakawa^{1, 2,} , Akari Kominami^{1, 2}, Michiyo Abe^{1, 2}, Kaori Yamamoto², Mayumi Nakao², Fumiko Nakaoka², Shigetoshi Okumura^{2, 3}, Lekh Raj Juneja^{2, 3} and Jun Kunisawa¹

¹Laboratory of Vaccine Materials, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan

²MG Pharma Inc., Osaka, Japan

³ROHTO Pharmaceutical Co., Ltd., Osaka, Japan

Cite this paper:
Yuka Sasakawa, Akari Kominami, Michiyo Abe, Kaori Yamamoto, Mayumi Nakao, Fumiko Nakaoka, Shigetoshi Okumura, Lekh Raj Juneja and Jun Kunisawa. “LICONINE^®”, an Extract of Glycyrrhiza Uralensis, Normalizes the Fecal Microbiota Disturbance in Diet-induced Obese Mice. Journal of Food and Nutrition Research. 2018; 6(8):509-512. doi: 10.12691/jfnr-6-8-4

Abstract

It has been reported that Glycyrrhiza uralensis (Ural licorice) extract, with the brand name “LICONINE^®”, at an intake level of low risk (human equivalent to less than 1 g licorice per day) had anti-obesity and anti-inflammatory effects on high-fat high-sucrose (HFS) diet-induced obese mice, but the effect of LICONINE on the fecal microbiota has not been clarified. In the present study, effects of LICONINE versus Ural licorice at intake levels of low risk on the fecal microbiota Bacteroidetes and Firmicutes were examined in HFS diet-induced obese mice. The results demonstrated that consumption of LICONINE was associated with higher decrease in the body weight and visceral fat weight than those with Ural licorice. The results also demonstrated that the Firmicutes to Bacteroidetes ratio in the feces was decreased more with LICONINE than with Ural licorice, and that the body weight and visceral fat weight were correlated with the Firmicutes to Bacteroidetes ratio in HFS diet-induced obese mice. These results indicate that LICONINE, at an intake level of low risk, may reduce obesity through the normalization of the fecal microbiota disturbance. In summary, at the intake level of low risk, LICONINE is more effective than Ural licorice for treating obesity and fecal microbiota disturbance. Further research is needed to identify the mechanisms underlying the effects of LICONINE on fecal microbiota.

Keywords:
glycyrrhiza uralensis ural licorice extract LICONINE high-fat high-sucrose diet-induced obese mice obesity microbiota

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	Sasakawa, Y., Kominami, A., Abe, M., Yamamoto, K., Nakao, M., Nakaoka, F., Okumura, S., Juneja, L.R. and Kunisawa, J., “The Anti-obesity and Anti-inflammatory Effects of “LICONINE™”, an Extract of Glycyrrhiza Uralensis, on Diet-induced Obese Mice and 3T3-L1 Mouse Adipocytes,” Journal of Food and Nutrition Research, 5(10). 781-788. 2017.
[2]	Ministry of Health, Labour and Welfare, Japan, “About handling of medical supplies contain glycyrrhizic acid,” The MHLW Ministerial Notification No. 158, February. 1978 (in Japanese).
[3]	Ley, R.E., Turnbaugh, P.J., Klein, S. and Gordon, J.I., “Microbial ecology: human gut microbes associated with obesity,” Nature, 444 (7122). 1022-1023. 2006.
[4]	Ley, R.E., Bäckhed, F., Turnbaugh, P., Lozupone, C.A., Knight, R.D. and Gordon, J.I., “Obesity alters gut microbial ecology,” Proceedings of the National Academy of Sciences of the United States of America, 102 (31). 11070-11075. 2005.
[5]	Turnbaugh, P.J., Bäckhed, F., Fulton, L. and Gordon, J.I., “Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome,” Cell Host & Microbe, 3 (4). 213-223. 2008.
[6]	Geary, R.C., “Testing for normality,” Biometrika, 34 (3-4). 209-242. 1947.
[7]	Ryan, T.A., “Multiple comparisons in psychological research,” Psychological Bulletin, 56 (1). 26-47. 1959.
[8]	Ryan, T.A., “Significance tests for multiple comparison of proportions, variances, and other statistics,” Psychological Bulletin, 57. 318-328. 1960.
[9]	Ozaki, M., Fujita, T., Kumagai, Y. and Otani, Y., “A retrospective study for determining the starting dose in first-in-human studies on Japanese healthy volunteers,” Japanese Journal of Clinical Pharmacology and Therapeutics, 37 (3). 119-126. 2006.
[10]	López-Cepero, A.A. and Palacios, C., “Asociation of the Intestinal Microbiota and Obesity,” Puerto Rico Health Sciences Journal, 34 (2). 60-64. 2015.